ITG offers radioisotopes for clinical applications as well as research purposes. We have therefore established a GMP manufacturing of a first-in-class radionuclides and -generator platform for the development of a new generation of targeted cancer diagnostics and therapies.
In 2016, ITG received Marketing Authorization for EndolucinBeta®. EndolucinBeta® respectively no-carrier-added (n.c.a.) Lutetium (177Lu) chloride is a radiopharmaceutical precursor and indicated for the radiolabeling of disease-specific carrier molecules. The emerging radio conjugates can be applied in Targeted Radionuclide Therapy for example in cancer treatment.
Get in touch with our Sales Team
If you are in need of any further information regarding isotopes and our worldwide service, please contact us:
Phone: +49 89 329 8986 600